Open AccessIncidence and Timing of Taper/Posttherapy–Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder
Author(s) -
Philip T. Ninan,
Jeff Musgnung,
Michael Messig,
Gina Buckley,
Christine J. Guico-Pabia,
Tanya Ramey
Publication year - 2015
Publication title -
primary care companion to cns disorders/the primary care companion for cns disorders
Language(s) - English
Resource type - Journals
eISSN - 2155-7772
pISSN - 2155-7780
DOI - 10.4088/pcc.14m01715
Subject(s) - discontinuation , placebo , incidence (geometry) , adverse effect , medicine , major depressive disorder , clinical endpoint , pediatrics , randomized controlled trial , physics , alternative medicine , pathology , amygdala , optics
The purpose of this post hoc analysis was to evaluate the incidence and timing of taper/posttherapy-emergent adverse events (TPAEs) following discontinuation of long-term treatment with desvenlafaxine (administered as desvenlafaxine succinate).